Current status of cetuximab for the treatment of patients with solid tumors.
about
Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.Ligand-directed profiling: applications to target drug discovery in cancer.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Implications of EGFR PharmDx kit for cetuximab eligibility.Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.The Gβ5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma.
P2860
Current status of cetuximab for the treatment of patients with solid tumors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Current status of cetuximab for the treatment of patients with solid tumors.
@ast
Current status of cetuximab for the treatment of patients with solid tumors.
@en
type
label
Current status of cetuximab for the treatment of patients with solid tumors.
@ast
Current status of cetuximab for the treatment of patients with solid tumors.
@en
prefLabel
Current status of cetuximab for the treatment of patients with solid tumors.
@ast
Current status of cetuximab for the treatment of patients with solid tumors.
@en
P2860
P356
P1476
Current status of cetuximab for the treatment of patients with solid tumors
@en
P2093
Deborah A Frieze
P2860
P304
P356
10.1345/APH.1G191
P407
P577
2006-01-10T00:00:00Z